A rare brain-attacking fungus is being detected more often across the United States, and doctors are on alert.
Story Snapshot
- Detections of Cladophialophora bantiana rose from 1–5 a year to 8 in 2024 and 14 in 2025.
- The fungus targets the brain and carries a 60%–70% fatality rate, according to federal data.
- Cases were identified by a single reference lab from samples sent by hospitals in over 20 jurisdictions.
- There is no national tracking system, so officials urge faster diagnosis and reporting.
Confirmed Rise in Detections from Specialized Laboratory Data
Centers for Disease Control and Prevention researchers reported that detections of Cladophialophora bantiana increased sharply in recent years. A clinical reference laboratory found eight detections in 2024 and 14 in 2025, up from one to five a year during 2009 through 2023. Doctors mostly found the fungus in brain tissue. Hospitals from more than 20 jurisdictions sent samples for testing over the study period. The pattern points to a real signal that deserves attention from clinicians and public health leaders.
The fungus is rare but dangerous. It tends to infect the central nervous system and can cause brain abscesses that are hard to treat. Federal summaries cite a case-fatality rate between 60% and 70% for these infections. Patients often arrive with headaches, seizures, or other neurologic signs. Because the disease is uncommon, doctors may not suspect a fungus at first. Delay can cost lives. The report urges faster recognition, consultation, and lab testing when symptoms and scans suggest a brain infection.
Why This Signal Matters Despite Limited National Tracking
There is no national surveillance program for this fungus, and experts still do not know the environmental source or exact route of infection. That gap means routine systems may miss cases. Specialized labs and clinician awareness fill part of the void. The Centers for Disease Control and Prevention also notes that fungal diseases are often underdiagnosed and underreported. In this setting, an increase seen in a trusted reference lab is an early warning. It tells hospitals to be ready and to send suspicious samples for testing.
Public health teams handle other fungal threats with formal reporting rules at the state level, but these rules differ by disease and by state. For Cladophialophora bantiana, there is no such unified framework. The current data come from one laboratory with broad-range fungal polymerase chain reaction tools. That focus brings strength and limits. It gives consistent methods over time, which helps show a trend. It also means the counts reflect who gets tested and referred. Officials call for wider awareness to reduce missed diagnoses.
What Clinicians and the Public Can Do Right Now
Clinicians can act on three fronts today. First, consider fungal causes when a brain abscess does not respond to usual care. Second, consult infectious disease and neurosurgery teams early. Third, send tissue or fluid to expert laboratories that can run molecular tests and guide treatment. These steps can speed the right therapy. They also add to the data picture. Even with rare diseases, steady reporting improves care and helps health agencies spot changes sooner.
🚨 BREAKING: Cases of a rare brain-infecting fungus are reportedly rising in the U.S. Cladophialophora bantiana can cause deadly brain infections, with a reported mortality rate of up to 70%.
— SARS‑CoV‑2 (COVID-19) (@COVID19_disease) October 15, 2026
For families, the risk to any one person is low, but the stakes are high if infection occurs. Ask clear questions when doctors order scans or discuss a suspected abscess. Timely care matters. This story also reflects a larger, bipartisan worry: systems built to track common threats can miss rare but deadly ones. Both conservatives and liberals are asking why basic public health tasks lag while costs rise. Clear rules, faster testing, and less red tape would help patients, not just agencies.
